Antiplatelet agents in cardiology: the choice of therapy (Q34019038)

30 July 2017

1 reference

title

Antiplatelet agents in cardiology: the choice of therapy (English)

1 reference

30 July 2017

S R Steinhubl

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

The Annals of Thoracic Surgery

30 July 2017

published in

1 reference

30 July 2017

volume

70

1 reference

30 July 2017

issue

2 Suppl

1 reference

30 July 2017

page(s)

S3-8

1 reference

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Development of aspirin resistance in persons with previous ischemic stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Thrombotic thrombocytopenic purpura after stenting and ticlopidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901608-8

10.1016/S0003-4975(00)01608-8

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference